Real-World CML drug side effects examined in 2,500 patients
NCT ID NCT07151820
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study analyzed insurance claims from over 2,500 people with chronic myeloid leukemia (CML) to see how often side effects from tyrosine kinase inhibitors (TKIs) occur and how they affect treatment changes and healthcare costs. Researchers looked at side effects that required medical attention. The goal was to understand the real-world burden of these side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tyrosine kinase inhibitors (TKIs)
- What this could lead to
- If successful, this could help doctors better manage side effects and reduce treatment disruptions for CML patients.
- What could go wrong
- This is an observational study using insurance claims data, not a controlled trial. It cannot prove cause and effect, and may miss side effects not recorded in claims.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, CHRONIC MYELOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.